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Abstract: Nonalcoholic steatohepatitis (NASH) is the main cause of chronic liver disease in the
Western world and a major health problem, owing to its close association with obesity, diabetes,
and the metabolic syndrome. NASH progression results from numerous events originating within
the liver, as well as from signals derived from the adipose tissue and the gastrointestinal tract.
In a fraction of NASH patients, disease may progress, eventually leading to advanced fibrosis,
cirrhosis and hepatocellular carcinoma. Understanding the mechanisms leading to NASH and its
evolution to cirrhosis is critical to identifying effective approaches for the treatment of this condition.
In this review, we focus on some of the most recent data reported on the pathogenesis of NASH and
its fibrogenic progression, highlighting potential targets for treatment or identification of biomarkers
of disease progression.
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is an expanding health problem, which varies
in prevalence among ethnic groups, occurring with an estimated global prevalence of 25% [1].
NAFLD associates with obesity, insulin resistance or type 2 diabetes and other metabolic abnormalities,
such as dyslipidemia and hypertension, collectively termed metabolic syndrome. In high risk populations,
the prevalence of NAFLD may be as high as 70%–90% [2,3]. NAFLD covers a spectrum of pathological
abnormalities. Although most patients have simple steatosis, around 7%–30% develop nonalcoholic
steatohepatitis (NASH), that in at least a third of cases progresses to advanced fibrosis or cirrhosis.
The tendency to develop hepatic steatosis differs among ethnic groups, with African-Americans having
a lower (24%) and Hispanics a higher (45%) frequency of the disease than Americans of European
descent (33%). The causes for these ethnic differences in prevalence of hepatic steatosis and liver injury
are not entirely understood.
NASH is characterized by hepatocellular damage, inflammation and fibrosis [4,5]. In general,
simple steatosis is considered a less severe form of NAFLD, although recent data indicate a possible risk
of progression [6,7]. In contrast, NASH is a significant risk factor for the development of cirrhosis and
hepatocellular carcinoma [8–10]. Although NASH was first documented more than 30 years ago [11],
its pathogenesis is still not fully elucidated. Initially, a two-hit hypothesis, based on appearance of
steatosis (first hit), followed by a second hit leading to inflammation, hepatocyte damage, and fibrosis,
was proposed by Day and James [12]. While accumulation of triglycerides is necessary for the
development of NASH, they may actually have a protective role against hepatocytes lipotoxicity,
which is mainly induced by fatty acids and derived metabolites such as diacylglycerols, acylcarnitines
or ceramides [13,14]. In addition, it is still unclear whether NASH develops sequentially, on the
grounds of a fatty liver, or it is rather a de novo response to a lipotoxic environment. The multiparallel
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hypothesis proposed more recently [15] suggests that NASH is the result of numerous conditions
acting in parallel, including genetic predisposition, abnormal lipid metabolism, oxidative stress,
lipotoxicity, mitochondrial dysfunction, altered production of cytokines and adipokines, gut dysbiosis
and endoplasmic reticulum stress. According to this hypothesis, hepatic inflammation in NASH may
even precede steatosis. As more contributing factors are continuously identified, a more complex
picture of NASH pathogenesis is emerging [16] (Figure 1).
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2. Genetic Factors
The relevance of genetic factor in the context of NASH has been recently and elegantly outlined
by twin studies [17]. A long list of genes potentially implicated in NAFLD appearance and progression
has been reported, and these data have been the subject of a recent review [18].
A significa t association with a SNP was identified in patatin-like phospholipase domain-
containing 3 (PNPLA3) on chrom some 22. The variant (rs738409 c.444 C>G, p.I148M), a on-synonymous
cytosine to guanine mutation resulting in isol uci e to methi nine conversion, correlates with increased
hepatic lipid con nt and predisposes to fatty liver- ssociated liver dise se, from simple steatosis to
steatohepatitis, fibrosis and he atocellular carcinoma [19,20]. PNPLA3 encodes for a 481 amino acid
protein, whose role has not bee fully elucidated. It appears to function as acylglycerol hydrolase,
acting on triacylglycerol, diacylglycerol, and monoacylglycerol [21,22]. Additional evidence indicates
that PNPLA3 also acts as lysophosphatidic acid acetyltransferase [23,24]. Overexpression of the
I148M variant in mouse liver promotes accumulation of triacylglycerol, increased synthesis of
fatty acids and impaired hydrolysis of triacylglycerol [25]. Moreover, the PNPLA3 genotype has
been reported to influence liver storage of retinol and retinol serum levels in obese subjects [26],
suggesting a potential role of PNPLA3 in regulating retinol metabolism and hepatic stellate cell (HSC)
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biology [27]. Remarkably, PNPLA3 has been recently shown to be expressed in hepatic stellate cells [28].
Interestingly, the prevalence of the PNPLA3 I148M allele varies considerably among different ethnic
groups, with the highest frequency in Hispanics (0.49), and lower frequencies in European Americans
(0.23) and African-Americans (0.17) [20]. This is in agreement with the different prevalence of NAFLD
in the three ethnic groups.
Carriage of a non-synonymous genetic variant in TM6SF2 (rs58542926 c.449 C>T, p.E167K)
on chromosome 19 (19p13.11) has been reported to correlate with steatosis and increased risk of
advanced fibrosis in NAFLD patients [29,30], independently of other factors, including diabetes,
obesity, or PNPLA3 genotype. The minor allele frequency in one of the NAFLD populations tested
was 0.12, compared to a frequency of 0.07 in a reference population. TM6SF2, is a transmembrane
protein localized in endoplasmic reticulum (ER) and ER–Golgi compartments and functions as
a lipid transporter [31]. The amino acid change E167K causes loss of function of TM6SF2 protein.
Studies performed in cell lines showed that downregulation of TM6SF2 reduces lipoproteins and
apolipoprotein B (APOB) levels, and increases hepatic deposition of triglycerides and the amount and
size of lipid droplets. In contrast, the size and number of lipid droplets diminishes when TM6SF2 is
overexpressed, indicating that TM6SF2 plays a role in regulating hepatic lipid efflux [29,31].
A broad spectrum of other genes has been associated with NAFLD. Polymorphism was reported
in genes involved in carbohydrate and lipid metabolism, insulin-induced pathways, as well as
inflammatory response, oxidative stress and fibrogenesis. A study by Dongiovanni et al. reported that
non-synonymous SNPs in ectoenzyme nucleotide pyrophosphate phosphodiesterase 1 (ENPP1 or PC1)
(rs1044498, K121Q) and insulin receptor substrate-1 (IRS1) (rs1801278, Q972R), are associated with
insulin resistance, through impairment of insulin receptor-mediated pathways, such as reduced AKT
activation, and promote fibrosis in NAFLD patients [32].
A functional non-synonymous variant (rs1260326, P446L) of glucokinase regulatory protein
(GCKR) has also been associated with NAFLD [33]. This variant produces a GCKR with defective
inhibitory function, leading to increased glucokinase activity and hepatic glucose uptake [34].
The resultant unimpeded hepatic glycolysis reduces glucose levels, inducing malonyl-CoA synthesis,
a substrate for lipogenesis that causes liver fat deposition and impairs mitochondrial β-oxidation.
A polymorphism in the solute carrier family 2 member 1 gene (SLC2A1), a glucose transporter, has been
reported in NAFLD subjects. SLC2A1 downregulation in hepatocytes results in lipid accumulation
and oxidative stress [35].
Several genes involved in oxidative stress have been investigated. Two reports correlated the
C282Y variant in hemochromatosis gene (HFE) with NASH and higher susceptibility to more severe
disease, as fibrosis or cirrhosis [36,37]. However, these findings have not been confirmed by other
studies [38–40]. Very recently, the rs641738 genotype at the MBOAT7-TMC4 locus, encoding for
the membrane bound O-acyltransferase domain-containing 7 was associated with more severe liver
damage and increased risk of fibrosis in patients with NAFLD. This effect has been ascribed to changes
in remodeling of the hepatic phosphatidylinositol acyl-chain [41].
3. Epigenetics
Epigenetic changes consist in modifications at the transcriptional level affecting gene expression
and phenotype. A number of epigenetic aberrations have been associated with NAFLD pathogenesis,
causing alterations in lipid metabolism, insulin resistance (IR), dysfunction of endoplasmic reticulum
(ER) and mitochondria, oxidative stress and inflammation [42]. The different epigenetic pathways
potentially involved in NAFLD are summarized in Figure 2.
Aberrant DNA methylation is a major epigenetic process in NAFLD development and progression
to NASH [43]. It occurs through methyltransferases (DNMTs) that catalyze the conversion of
cytosine to 5-methylcytosine [44], leading to gene silencing. It has been reported that mice fed with
a methyl-deficient diet show reduced levels of hepatic S-adenosylmethionine (SAM), associated with
methylation of genes involved in DNA damage and repair, lipid and glucose metabolism and
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fibrosis progression [45]. In agreement, food-derived methyl donors, such as folate, betaine and
choline, responsible for SAM synthesis, counteract DNA methylation [46] whereas folate deficiency
correlates with enhanced fatty acid synthesis and hepatic accumulation of triglycerides (TG) via
DNA methylation [47]. Methyl donor supplementation reverts liver lipid deposition induced by
high fat/high sucrose-diet, lowering global hepatic DNA methylation and methylation levels of the
promoter regions of different regulatory factors [48]. Betaine has been demonstrated to diminish
the methylation levels of the promoter of microsomal triglyceride transfer protein (MTP), enhancing
hepatic TG export and ameliorating liver steatosis in mice administered a high-fat diet (HFD) [43].
In addition, epigenetic changes of peroxisome proliferator-activated receptor gamma (PPARγ) in the
liver of NAFLD patients seems to promote IR [49].
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Although most epigenetic alterations are tran i nt, DNA methylation can be inherited from
parents [50]. It has been reported that maternal Western diet during prenatal time can increase the
susceptibility to NAFLD of male progeny [51]. Novel evidence indicates that mitochondrial DNA
(mtDNA) methylation may also play a role in NAFLD pathogenesis [52,53]. Liver methylation of
NADH dehydrogenase 6 (MT-ND6) correlates with NAFLD severity, resulting in significantly lower
expression of MT-ND6 mRNA in NASH than in patients with simple steatosis [54].
Histone acetylation, regulated by histone acetyltransferases (HATs) and histone deacetylases
(HDACs), has bee extensively associated with NAFLD [55,56]. High-fat mater al diet was shown to
lead to depletion of fetal hepatic HDAC1, su gesting that diet-induced maternal obesity can alter fetal
chromatin via histone modifi ations [55]. Carb hydrate-responsive element-binding protein (ChREBP),
an activator of lipogenic and glycolytic pathways involved in NAFLD progression, is regulated by
the HAT activator p300. Glucose-activated p300 induces ChREBP hyperacetylation, stimulating its
transcriptional activity and hepatic lipogenesis in mice, and p300 overexpression is associated with
steatosis and IR [56].
NAFLD has been also correlated with histone methylation. Lipid accumulation in the liver of HFD
mice has been associated with H3K4 and H3K9 histone trimethylation of peroxisome proliferator-activated
receptor alpha (PPARα) and lipolysis-related genes [57]. In addition, trans-generational changes in histone
methylation prom te lipogenesis and ER stress, cting on endop asmic reticulum ox doreductin 1α
(ERO1α) and liver X receptor α (LXRα) [58].
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Sirtuins (SIRTs) belong to the silent information regulator-2 family. SIRT1 deacetylation has been
recognized as a regulatory mechanism for several proteins involved in NAFLD pathogenesis [59]
and low SIRT1 expression has been observed in NAFLD models [60]. In addition, SIRT1-mediated
regulation of fetal metabolome and epigenome has been reported under maternal HFD [61]. SIRT3 is
localized in mitochondria and regulates fatty acid oxidation. SIRT3 knockout mice fed HFD develop
hepatic steatosis and IR [62].
MicroRNAs (miRNAs) modulate gene expression via post-transcriptional mechanisms,
regulating the main cellular processes, such as lipid metabolism, inflammation, apoptosis, cell growth
and differentiation. In the last few years, aberrant miRNA expression has been reported in a number
of diseases including metabolic disorders [63,64], whereas an increasing number of dysregulated
miRNAs, implicated in fatty acid synthesis, uptake and storage of triglycerides or oxidation,
have been recently identified in NAFLD [65] (Table 1). Among these, miR-122, which negatively
regulates hepatic lipogenesis, is reduced in NASH patients [66] whereas miR-34a, that induces
β-oxidation and inhibits synthesis of fatty acids via a sirtuin1/5′ adenosine monophosphate-activated
protein kinase/3-hydroxy-3-methylglutaryl-CoA reductase (SIRT1-AMPK-HMGCR) mechanism,
is upregulated in NAFLD patients [67]. miRNA-33a has been recently reported to participate
in NASH development, counteracting cholesterol 7alpha-hydroxylase (CYP7A1). Sterol response
element-binding protein 2 (SREBP2) binds to its own gene promoter to induce miR-33a, which leads
to a decrease in cholesterol efflux to HDL and bile acid synthesis in Cyp7a1-tg mice [68]. In addition,
miR-33a inhibits CYP7A1 and bile acid synthesis to inhibit cholesterol catabolism.
Table 1. Modulation of miRNA expression relevant to NAFLD/NASH. ∆ indicates up- (↑) or
downregulation (↓). CYP7A1: cholesterol 7α1-hydroxylase; SREBP2: sterol response element-binding
protein 2; SIRT1: sirtuin1; AMPK: 5′ adenosine monophosphate-activated protein kinase; HMGCR:
3-hydroxy-3-methylglutaryl-CoA reductase; FAS: fatty acid synthase; ACC: Acetyl-CoA carboxylase;
mTOR: mammalian target of rapamycin; ROS: reactive oxygen species; RAC1: Ras-related C3
botulinum toxin substrate 1; ?: mechanism and/or target unknown.
miR ∆ Disease Model Role Validated/Predicted Target Reference
33a ↑ NASH Mouse Liver Cholesterol and bileacid homeostasis CYP7A1, SREPB2 [68]
34a ↑ NAFLD/NASH Human Biopsies Lipid homeostasis SIRT1-AMPK-HMGCR [67,69]
103a2 ↑ NAFLD Human Biopsies Insulin signaling,metabolism, inflammation ? [30,70]
160b ↑ NAFLD Human Biopsies Insulin signaling ? [30]
122 ↓ NASH HFD mice/Human Biopsies
Lipid and cholesterol
metabolism
HMGCR, FAS,
SREBP1/2, ACC [66,71]
301a-3p ↑ Steatosis/NAFLD/NASH Human Biopsies ? ? [69]
375 ↓ NAFLD/NASH/Cirrhosis Human Biopsies ? ? [69]
576-5p ↑ NAFLD Human Biopsies
Insulin signaling,
metabolic homeostasis,
inflammation
mTOR signaling,
ephrin B signaling,
ROS production,
RAC1
[70]
892a ↑ NAFLD Human Biopsies Kupffer cell activation ? ? [70]
I137 ↑ NAFLD Human Biopsies ? ? [70]
1282 ↓ NAFLD Human Biopsies Insulin signaling,metabolism, inflammation ? [70]
3663-5p ↑ NAFLD Human Biopsies Insulin signaling,metabolism, inflammation ? [70]
3924 ↑ NAFLD Human Biopsies Insulin signaling,metabolism, inflammation ? [70]
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More recently, other dysregulated miRNAs have been identified in NAFLD livers [70].
Among these, the most significantly upregulated (miR-103a-2, miR-106b, miR-576-5p, miRPlus-I137,
miR-892a, miR-1282, miR-3663-5p, and miR-3924) play critical roles in insulin signaling, metabolism
homeostasis, inflammation and cancer. In particular, miR-576-5p influences multiple pathways implied
in NAFLD, including mammalian target of rapamycin (mTOR), a kinase modulated by insulin that
induces hepatic lipogenesis through a PPARγ-dependent mechanism [72]. miR-576-5p also regulates
eukaryotic translation initiation factor 4 (eIF4), p70S6 kinase (p70S6K) and phosphatidylinositol-
4,5-bisphosphate 3-kinase (PI3K), pathways associated with insulin action and metabolic control.
Moreover, a direct target of miR-576-5p is the small GTPase RAC1, which promotes lipotoxicity
via c-Jun N-terminal kinase (JNK) activation. RAC1 is negatively modulated by miR-576-5p,
triggering a protective effect against NAFLD progression [72]. Finally, in a study conducted in
biopsy-staged NAFLD patients, increased miR-301a-3p and miR-34a-5p and decreased miR-375
significantly correlated with disease progression [69].
4. Dietary Factors
Lifestyle changes focusing on weight loss remain the keystone of NAFLD and NASH
treatment [73]. Recent reports indicate that lifestyle modifications based on decreased energy intake
and/or increased physical activity during 6–12 months cause improvement in biochemical and
metabolic parameters and reduce steatosis and inflammation [74]. Conversely, increased consumption
of sugar-sweetened food and beverages has been associated with NAFLD development and
progression. High intake of fructose, used as food and drink sweetener, is implicated in NAFLD
pathogenesis through several mechanisms. In addition, a fructose-enriched diet contributes to induce
liver fibrosis in animal models of NASH [75]. Via the portal vein, dietary fructose reaches the
liver in high concentrations, exerting a lipogenic action by activation of the transcription factors
SREBP1 and ChREBP and subsequent induction of acetyl-CoA carboxylase (ACC) 1, fatty acid
synthase (FAS) and stearoyl-CoA desaturase 1 (SCD1) [76]. These effects persist in liver-specific
insulin receptor knockout mice, indicating that fructose stimulates lipogenesis independently of
insulin signaling [77]. Fructose-induced de novo lipogenesis (DNL), enhancing malonyl-CoA
concentration, inhibits mitochondrial β-oxidation and decreases mitochondrial ATP production [78].
In addition, fructose stimulates lipogenesis by inducing ER stress and subsequently activating the
transcription factor X-box binding protein 1 (XBP1), which, in turn, upregulates lipogenic enzymes,
as demonstrated in mice fed with a 60% fructose diet [79]. In concomitance, phosphorylation
of fructose to fructose-1-phosphate leads to depletion of hepatic ATP and increase in ADP and
inosine monophosphate (IMP), which is converted to uric acid [80], that promotes steatosis inducing
mitochondrial oxidative stress [81]. Generation of reactive oxygen species (ROS) is also induced by
fructose metabolism [82], and nutrient-derived ROS have been associated with enhanced steatosis via
insulin-independent PI3K pathway [83]. Moreover, upregulating ketohexokinase, fructose potentiates
its own metabolism and ketohexokinase inhibition leads to decreased fatty liver and reduced liver
inflammation in high-fat/high-sucrose fed mice [84]. Finally, fructose-induced metabolic disorders can
be mediated by epigenetic changes, such as alterations in genomic or mitochondrial DNA (mtDNA)
methylation [85,86].
Dietary iron overload has been recently implicated in NASH pathogenesis. A study by
Handa et al. [87] shows that dietary iron excess leads to a severe NASH phenotype in an obese,
diabetogenic mouse model characterized by oxidative stress, inflammation and ballooning.
Different molecular mechanisms are involved, including upregulation of cytokines (interleukin 6, IL-6,
tumor necrosis factor α, TNFα) and immune mediators (Toll-like receptor 4, TLR4, inducible nitric
oxide synthase, NOS, interferon gamma, IFNγ), and induction of inflammasome related factors
(NOD like receptor 3, NLRP3, interleukin 18, IL-18) and genes associated with lipid metabolism.
Moreover, emerging evidence indicates that hepatic copper (Cu) deficiency is associated with NAFLD
development and progression. In an experimental rat model, a Cu deficient diet coupled with
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high sucrose intake provoked NASH, even in the absence of obesity or severe steatosis. Rats fed
low-Cu/high-sucrose diet displayed enhanced liver expression of lipogenic enzymes, such as ATP
citrate lyase (ACLY) and FAS, and of inflammatory and pro-fibrogenic factors (TNFα, C–C motif
chemokine CCL2, CCL3), together with hepatic stellate cell activation. While low Cu alone promotes
lipid peroxidation, as indicated by increased levels of malondialdehyde (MDA), its combination with
high sucrose (or fructose), that causes a further reduction of hepatic Cu, causes insulin resistance
and liver damage, with hepatocyte ballooning and occurrence of Mallory-Denk bodies. In addition,
Cu deficiency influences Fe retention and partitioning in animals as well as in NAFLD patients [88].
Several lines of evidence correlate hepatic free fatty acids (FFAs) and free cholesterol (FC)
accumulation to NAFLD pathogenesis. Dysregulation of lipid homeostasis plays an essential role
in NAFLD pathogenesis, induced by a surplus of dietary free fatty acids, enhanced DNL and
augmented lipolysis [89]. Rather than total hepatic fat content, the role of specific lipid classes
in the development and progression of NAFLD is emerging [90]. In particular, accumulation of
different lipids as well as upregulation of distinct enzymes mediating DNL was found to be associated
with macrovesicular or microvesicular steatosis, the latter correlating with mitochondrial dysfunction
and NAFLD [91]. Among toxic lipids, saturated fatty acids have been shown to be elevated in
NASH patients [92] and induce inflammation and hepatocyte apoptosis by activating JNK and
mitochondrial pathways. Other lipids having a role in NAFLD include ceramide, diacylglycerol
(DAG) and sphingosine [90,93–96]. In particular, DAG and ceramide impair insulin capability to
stimulate glycogen synthesis and suppress gluconeogenesis, through protein kinase-C epsilon (PKCε)
activation [97]. In contrast, unsaturated fatty acids do not affect cell viability and an increase in their
content leads to enhanced hepatic synthesis of TG. In turn, TG accumulation is not toxic but may
protect the liver from the excessive deposition of toxic TG precursors [98,99]. Omega-3 polyunsaturated
fatty acids (PUFAs) plasma levels are reduced in patients with NASH. However, pharmacologic
supplementation did not induce an amelioration of the histologic picture of NASH [100], and in
an experimental model it was even associated with more severe damage [101].
Emerging evidence underscores the role of cholesterol as a prominent risk factor for
the pathogenesis of NAFLD/NASH. In humans a progressive increase in hepatic FC during
NAFLD progression to NASH has been observed [102,103]. In experimental models increase
in dietary cholesterol has been shown to promote hepatic inflammation and fibrosis [104–106],
whereas a cholesterol-free diet ameliorates NASH [107]. The molecular mechanisms underlying FC
accumulation during NASH development are multiple and only partially elucidated. Current data
indicate that cholesterol homeostasis is dysregulated in NAFLD, due to an increase in cholesterol
synthesis and uptake or dysfunction in cholesterol metabolism. Accordingly, the activity of two key
regulators of cholesterol synthesis, HMGCR and SREBP2, is elevated in NASH patients [103,108,109].
Similarly, expression analysis of genes involved in cholesterol metabolism reveals a number of altered
pathways in individuals with NASH [108].
Cholesterol uptake from lipoproteins is mediated by different proteins, including the low density
lipoprotein receptor (LDLR) and the scavenger receptor class B type I (SR-BI) [110]. Hepatic uptake
of LDL-cholesterol occurs via the scavenger receptor pathway in unrestrained manner, leading to
deposition of cholesterol crystals in hepatocytes and generation of foamy Kupffer cells, two critical
features of NASH [111,112]. Intracellular accumulation of free cholesterol represents a key event
for inflammasome activation and inflammatory response [112] and sensitizes cells to transforming
growth factor beta (TGF-β), TNF-α and Fas, leading to liver damage and disease progression [104,113].
Moreover, LDL cholesterol can be oxidized to oxidized low-density lipoprotein (oxLDL) cholesterol,
which has been found in high concentrations in the plasma of NASH patients [114] and induces
proinflammatory cytokine secretion accumulating in lysosomes of Kupffer cells [111,112]. Recently,
a reduced efflux of FC has been observed in injured (foam) hepatocytes of NAFLD patients,
associated with reduced expression of ATP-binding cassette sub-family G member 8 (ABCG8),
which regulates cholesterol excretion trough the bile [108]. In addition, decreased expression of
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CYP7A1 and CYP27A responsible for cholesterol transformation into bile acids (BA) has been found
in human NAFLD/NASH [108], as well as in a rat model of NASH induced by dietary cholesterol
overload [115].
Oxysterols, the oxidative products of cholesterol generated during bile acid synthesis, have been
described to induce liver damage through mitochondrial impairment. A study by Bellanti et al. [116]
shows that mice fed high fat/high cholesterol (HF/HC) exhibit high levels of toxic oxysterols, such
as triol, and oxidative stress and mitochondrial dysfunction associated with NASH. Accordingly,
Huh7 and primary rat hepatocytes co-exposed to triol and palmitic or oleic acid, undergo apoptosis,
mediated by impaired mitochondrial respiratory chain [116]. Finally, besides the effects on liver,
cholesterol contributes to NASH pathogenesis also by stimulating inflammatory reactions in other
tissues, such as adipose tissue and arterial wall, representing a key factor in the multiparallel scenario
concurring to NASH [117,118].
5. Mitochondrial Dysfunction and Apoptosis
Oxidative stress has been recognized as a major factor in the pathogenesis of NASH. Based on
the evidence that a high amount of intracellular ROS are generated in mitochondria and ROS
overproduction is elicited in the presence of respiratory chain disruption, mitochondrial impairment
has been suggested as a main event in NASH development [83,119,120]. Along these lines, structural
and functional defects in mitochondria have been reported in patients with NASH [121,122].
Several mechanisms contribute to mitochondrial impairment and subsequent hepatic cell
injury during NASH, mainly associated with lipotoxicity. It has been shown that, following lipid
accumulation, water and calcium influx in mitochondria is increased, due to lower phosphorylation
of the voltage dependent anion channel (VDAC) in the mitochondrial outer membrane, resulting in
cytochrome c release and cell death [123]. Lipotoxic effects in mitochondria are also mediated
by JNK; high concentrations of palmitate cause mitochondrial dysfunction and apoptosis through
phosphorylation of Sab (SH3BP5), a mitochondrial outer membrane substrate of JNK [124],
whereas free cholesterol accumulation in the liver of NASH mice induces mitochondrial permeability,
ROS production and apoptosis through JNK1. An emerging role for NAD+ in mitochondrial stress
induction during NASH development has been recently shown. Gariani et al. demonstrated
that mice fed high-fat/high-sucrose exhibit impaired mitochondrial function associated with lower
hepatic NAD+ levels [125]. Conversely, NAD+ repletion displays a protective effect against NAFLD,
probably mediated by the induction of mitochondrial unfolded protein response (UPRmt), an adaptive
mechanism dependent on the histone deacetylases SIRT1 and SIRT3, aimed to enhance mitochondrial
activity and hepatic β-oxidation [126]. Furthermore, recent studies have suggested a role for coenzyme
Q (CoQ), which is essential for mitochondrial respiration, in NAFLD development and progression to
NASH [127–130]. Abnormal concentrations of CoQ have been found in plasma and liver of NAFLD
patients [131] and perturbation in CoQ metabolism was observed in experimental NAFLD during
disease progression [132,133].
Other key inducers of mitochondrial dysfunction are lysosomal permeabilization, which is
frequently observed in NAFLD patients and associated with caspase activation [134], and ROS
generation. CYP2E1 promotes oxidative stress, inflammation and protein modifications, by hydrolyzing
molecules such as fatty acids and ethanol into toxic metabolites, including ROS, which cause respiratory
chain disruption and mitochondrial damage [135], resulting in hepatocyte injury and progression to
NASH [136].
6. Necroptosis
Necroptosis is a recently described cell death mechanism, morphologically comparable to
necrosis, but consisting in definite biochemical pathways that occur in a programmed mode [137]
and are potentially involved in inflammatory disorders, including liver diseases. Necroptosis can be
initiated by activation of multiple signals, such as toll-like receptors, death receptors and others,
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which lead to the assembly of the necrosome, a multiprotein complex consisting in caspase-8,
Fas-Associated protein with Death Domain (FADD), cellular FLICE/caspase 8-like inhibitory protein
(cFLIP), and receptor-interacting proteins 1 and 3 (RIP1 and RIP3) [138]. RIP1–RIP3 interaction initiates
necroptotic signaling [139]; RIP3 phosphorylates mixed lineage kinase domain-like protein (MLKL),
which oligomerizes and translocates to the plasma membrane causing irreversible membrane damage
and consequent cell death [140]. In specific cell setting, RIP3 can mediate necroptosis independently
of RIP1 [141–143]. In other cell contexts, a RIP3 dependent ROS production may play an additional
role [144,145].
Recently, necroptosis has been proposed as a novel mechanism in the pathogenesis of NAFLD
both in humans and experimental models. Gautheron et al. found that RIP3 was overexpressed and
mediated liver inflammation, activation of hepatic progenitor cells/cholangiocytes and liver fibrosis
in NASH patients and in the methionine/choline-deficient (MCD) mouse model of steatohepatitis.
They observed that RIP3 induces JNK activation, leading to release of pro-inflammatory mediators,
such as CCL2, that further sustain RIP3-dependent signaling, cell death, and liver fibrosis.
RIP3-induced pathways were blocked by caspase-8. [146]. A study by Afonso et al. [147] confirmed that
hepatic levels of RIP3 are significantly augmented in steatohepatitis and showed that RIP3-dependent
MLKL activation is increased in the liver of NAFLD patients as well as in MCD-induced experimental
NASH. Moreover, lack of RIP3 ameliorates liver injury, steatosis, inflammation and fibrosis in
experimental NASH.
7. Endoplasmic Reticulum Stress
ER stress has been implicated in a number of liver diseases, including NASH. ER dysfunction,
ATP depletion or other stimuli induce the unfolded protein response (UPR), an adaptive mechanism
directed to avoid luminal accumulation of defective proteins and apoptosis initiation. In NAFLD,
a cross-talk between insulin signaling and UPR has been reported, involving XBP–1/PI3K interaction
and consequent XBP-1 nuclear translocation [148]. Other pathways activated by cellular response
to ER stress involve JNK, an activator of inflammation and apoptosis implicated in NAFLD
progression to NASH [90] and SREBP-1c, which induces liver fat accumulation, worsening ER
stress [149]. In vitro studies show that exposure of hepatic cells to a lipotoxic concentration of
palmitate, a saturated fatty acid (SFA), is associated with ER calcium depletion, ROS accumulation and
apoptosis [92,150,151]. In fact, increased SFA incorporation in ER membrane, as well as altered
phosphatidylcholine/phosphatidylethanolamine ratio, induces disruption of ER membrane and
impairment of sarcoendoplasmic reticulum calcium ATPase (SERCA) function, causing a net calcium
efflux from ER stores and its subsequent translocation to the mitochondria, with dysregulation of
mitochondrial metabolism and oxidative stress. Accordingly SERCA activity is impaired in obese
livers [152] and overexpression of SERCA in obese mice improve hepatic ER stress, indicating that
SERCA plays a crucial role in lipotoxic-induced ER stress and, indirectly, in mitochondrial
dysfunction [152].
8. Hypoxia
In experimental NASH, hypoxia causes alterations in lipid homeostasis, upregulating genes
involved in lipogenesis, such as SREBP-1c, PPARγ, ACC1 or 2 and downregulating genes implied in
lipid metabolism, such as PPARα and carnitine palmitoyltransferase-1 (CPT-1) [153]. Besides lipid
metabolism, insulin signaling is also affected and under hypoxic conditions hepatic upregulation of
inflammatory cytokines and profibrogenic genes was observed [154]. Moreover, reduced oxygen
availability induces secretion of adipokines and inflammatory cytokines in adipose tissue [155],
contributing to alter lipid metabolism and glucose homeostasis [156,157]. These effects are mediated by
hypoxia-inducible transcription factors (HIF-1α and HIF-2α) that regulate cellular response to oxygen
deficiency and can be also activated by other stimuli, including oxidative stress or inflammatory
signals [158]. In particular, HIF-1α transcription is induced by nuclear factor kappa-B (NF-κB),
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and NF-κB activity is crucial for HIF-1α accumulation under oxygen deprivation [159]. Furthermore,
hypoxia has been reported to modulate inflammation by regulating TLR expression and function
through HIF-1 [160,161]. Along these lines, it is conceivable that the proinflammatory state observed in
obese NAFLD patients may be enhanced by hypoxia, due to a positive feedback mechanism involving
HIF-1α and NF-κB, explaining the exacerbation of liver injury in NAFLD subjects in the presence of
obstructive sleep apnea-hypopnea syndrome (OSAHS) [162].
9. Inflammation
Inflammation represents a crucial aspect in NASH pathogenesis. Overload of toxic lipids,
mainly FFA, causes cellular stress and induces specific signals that trigger hepatocyte apoptosis,
the prevailing mechanism of cell death in NASH, correlating with the degree of liver inflammation
and fibrosis [163]. Signaling pathways induced by key death receptors, such as TNF-related
apoptosis-inducing ligand (TRAIL-R), Fas and tumor necrosis factor receptor (TNFR), are upregulated
in NASH, indicating they may have a role in promoting inflammation and chemokine secretion.
Although the precise role of Fas and TNFR in NASH in vivo is still controversial, it has been shown
that lack of TRAIL-R is protective, as TRAIL-R-deficient mice display reduced steatosis, inflammation
and fibrosis in association with lower hepatocyte apoptosis [164]. Moreover, prolonged ER stress and
mitochondrial dysfunction, two critical events in NAFLD, have been reported to induce apoptosis
through TRAIL-R/caspase 8 [165].
Different types of immune cells are recruited and/or activated to the site of injury, contributing to
NAFLD development and progression. Kupffer Cell (KC) activation is critical in NASH and precedes
the recruitment of other cells [166]. Lanthier et al. [167] have shown that KC depletion increases insulin
sensitivity and ameliorates inflammation and fibrosis. Depending on the settings, different polarization
forms have been described for KCs, mainly classified in two phenotypes: M1, pro-inflammatory and
M2, considered primarily immunoregulatory [168]. However, markers of both M1 and M2 forms can
be expressed at once [169]. Differentiation of KCs towards a M1 phenotype is principally driven by
pathogen-associated molecular patterns (PAMPs) that, interacting with TLRs, induce the secretion of
various cytokines, such as IL-1β, IL-12, TNF-α, CCL2 and CCL5, concurring to further hepatocyte
damage and release of damage-associated molecular patterns (DAMPs). DAMPs, in turn, act on TLRs
amplifying KCs activation and inflammation. In addition, some cytokines (i.e., CCL2 and CCL5),
induce HSC activation, initiating a fibrogenic response [170]. Activation of KCs in NAFLD is also
triggered by toxic lipids, that upregulate TLRs and augment the response to lipopolysaccharide
(LPS) [171]. KCs displaying the M2 phenotype produce several factors with anti-inflammatory
properties, as IL-4, IL-10, IL-13 and TGF-α [168,169], but different subtypes have been identified
with diverse actions. Although it has been reported that induction of peroxisome proliferator-activated
receptor delta (PPARδ) drives KCs toward the M2 form, reducing obesity-induced insulin resistance in
mice [172], the role of M2 KCs in NAFLD is still not elucidated [168].
Despite potent antimicrobial and phagocytic properties, neutrophils display scarce specificity.
Excess of neutrophil recruitment in NASH crucially contributes to hepatocyte damage, inflammation
and fibrosis, through the release of different factors [173,174], including cytotoxic enzymes as
myeloperoxidase and elastase. Myeloperoxidase-deficient mice show moderated NASH, associated
with lower hepatic secretion of inflammatory cytokines [175]. Similarly, deletion of neutrophil elastase
attenuates liver inflammation in experimental NAFLD [176].
Dendritic Cells (DCs) counteract sterile inflammation acting as antigen-presenting cells and
eliminating cell debris and apoptotic cells. Studies aimed to establish DCs’ function in NASH have
shown controversial results [177]. An anti-inflammatory and antifibrotic role of DCs in NASH
is suggested by the fact that liver depletion of these cells exacerbates inflammation and fibrosis.
According to the study by Henning et al liver infiltrating DCs activate and secrete IL-6, TNF-α and
CCL2 [178]. In contrast, other findings report that avoiding the accumulation of DCs subtypes
expressing high levels of inflammatory factors limits liver injury in experimental NASH [179].
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Natural Killer (NK) cells in the liver are stimulated through several receptors upon interaction
with other hepatic cells. In NASH, activation of NK can be achieved by a broad number of ligands
and cytokines, but the role of these cells in NAFLD pathogenesis is still controversial [180,181].
Two different phenotypes of NKT cells have been recently associated with liver disease, acting in
opposite modes during sterile inflammation: proinflammatory type I and protective type II cells [182].
Although NKT type I cells can be activated by lipids, suggesting their possible involvement in NAFLD,
NKT-deficient mice fed HFD are more prone to steatosis and weight gain than wild type mice [183].
In addition, adoptive transfer of NKT cells in leptin-deficient mice ameliorates glucose metabolism
and diminishes fatty liver [184]. Furthermore, depletion of NKT can result in activation of KC and
secretion of IL-12 [184]. Conversely, clinical studies performed in patients with different stages of
NAFLD demonstrate that NKT cells tend to increase in the liver during disease progression [185].
According to these data, NKT cells seem to be depleted in early NAFLD to enhance in the later phases,
participating in inflammation and fibrosis [186].
10. Hedgehog
Hedgehog (Hh) is a well-characterized factor implied in the fibrogenic process of several organs,
including the liver. Hh pathway activation is proportional to the severity and persistence of injury [187],
induces a cascade of events concurring to wound healing response and involves various cell types,
including damaged ballooned hepatocytes, inflammatory cells (mainly NKT cells and macrophages),
ductular/progenitor cells and HSCs [188].
The Hh pathway was associated with severe NASH in a gene profiling study where patients with
different severity of the disease were included [189]. In experimental NASH, the Hh pathway leads to
proliferation and activation of ductular progenitor cells and HSC, that, in turn, produce Hh ligands
and, consequently, soluble mediators such as osteopontin and CXCL-16, responsible for immune
cells recruitment and damage progression [190,191]. Moreover, Patched-heterozygous deficient mice,
characterized by hyperactivation of the Hh pathway, show exacerbation of the disease following
a NASH-inducing diet, whereas liver-specific inhibition of Smo prevents diet-induced liver damage
and fibrosis, despite hepatic lipid accumulation [190].
Caspase-2 has been recently identified as a critical factor in NASH pathogenesis, mediating
hepatocyte lipoapoptosis. Hepatic caspase-2 was found to be increased both in human and experimental
NASH, in association with profibrogenic factors, such as Hh-related genes. When challenged with
a HF diet or fed a MCD diet, caspase-2 knockout mice showed lipid-induced hepatic apoptosis,
together with decreased activation of Hh signaling and fibrosis [192].
In NAFLD patients, Hh activity and Hh ligands’ expression correlates with the degree of
fibrosis [193] and elevated Hh activation is associated with hepatocyte ballooning, high presence
of progenitor cells and myofibroblasts and portal inflammation [187]. In agreement with these findings,
the Pioglitazone vs. Vitamin E vs. Placebo for treatment of NASH (PIVENS) trial demonstrated that
amelioration of NASH in response to treatment was associated with a marked decrease of Sonic Hh
ligand (Shh) expressing hepatocytes [194].
11. Nuclear Receptors
Nuclear receptors are ligand-dependent transcription factors that regulate glucose and lipid
metabolism in the liver. Nuclear receptors are divided into seven subfamilies named as NR0-NR6 [195]
and NR1 subfamily is of particular importance in NAFLD. This latter group of nuclear receptors
is retained in the nucleus and heterodimerizes with the retinoid X receptor (RXRα) [195,196] and
includes: NR1C1-3 (the peroxisome proliferator-activated receptors, PPARα, β, γ), NR1H2-3 (the liver
X receptors, LXRα, β), NR1H4 (the farnesoid X receptor, FXRα), NR1I2 (the constitutive androstane
receptor, CAR), and NR113 (the pregnane X receptor, PXR). PPARs inhibit inflammation in the
obese state acting on NF-κB and AP1 transcription factor and regulate metabolism by inducing
transcription of adiponectin (PPARγ) and fibroblast growth factor-21 (FGF21) (PPARα and FXR) [195].
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PPARα regulates β-oxidation and cholesterol removal during the fasting state or when metabolism
increases in adipose and/or muscle tissues [195]. Hepatic PPARα expression decreases in NAFLD
leading to steatosis, but is enhanced following diet and exercise [197,198].
In animal models of steatosis and steatohepatitis, the use of PPARα activators improves the
disease [199,200]. In addition, several studies in mice suggest that induction of both PPARβ/δ and
PPARγ ameliorates steatosis [201,202]. Indeed, animals treated with PPARα activators show less
weight gain than controls, lower levels of epididymal fat, and are protected from atherosclerosis [203].
PPAR activation may also ameliorate fibrosis, since NASH patients treated with pioglitazone (a PPARγ
agonist) had improved fibrosis biomarkers [204]. Recent studies show that PPARγ downregulates
adipocyte endothelial nitric oxide synthase (eNOS), a molecule that contributes to IR and development
of NASH [205]. Since the use of selective PPARα agonists has proven quite ineffective against
NAFLD [197] the use of mixed receptor agonists (PPARα and PPARβ/γ) is underway in the therapy
for NASH patients and recent results have been reported [206].
PXR, expressed in many tissues but mainly in the liver [207], is released not only by hepatocytes,
but also by Kupffer and stellate cells [208]. Two polymorphisms of this gene have been associated
with augmented severity of NAFLD: rs7643645/G and rs2461823 [209], whereas a variant encoding
a short dominant negative PXR isoform, which inhibits the full-length isoform activity, has been
recently described [210]. PXR regulates various genes involved in xenobiotic and drug metabolism,
including enzymes [211] that play a role in the oxidative metabolism of lipophilic compounds such as
steroids, fatty acids, bile acids, drugs, retinoids, and xenobiotics. PXR activation has been associated
with increased severity of steatosis, obesity, insulin resistance and hypercholesterolemia as it enhances
hepatic fatty acid uptake and lipogenesis, while it decreases β-oxidation [212,213]. The role of PXR in
experimental NAFLD is more complex. While PXR knockout mice are resistant to obesity, they show
impaired glucose tolerance, hyperleptinemia and hypoadiponectinemia, together with elevated fasting
glucose levels [212]. Recently, it was shown that PXR activation inhibits the production of many
NF-κB target genes and increases the production of secreted interleukin-1 receptor antagonist (IL-1RA),
reducing the effects of LPS-induced inflammation [214].
Human CAR1-3, expressed mainly in liver and intestine and to a lower extent in other tissues [215],
is implicated in protection against toxic food or contaminants [216]. CAR is also associated with lipid
metabolism and inflammation in NAFLD. CAR increases in the liver in the fed state, reducing hepatic
steatosis, inflammation, insulin resistance and hypercholesterolemia [217]. In animal models,
treatment with an agonist of CAR ameliorates diet-induced obesity, hepatic steatosis and diabetes [218].
Moreover, in knockout mice for the low density lipoprotein receptor (LDLR), activation of CAR reduces
triglycerides and cholesterol plasma levels [219]. Recently, it has been reported that activated CAR
translocates into the nucleus and functions as an adaptor protein to recruit PGC1α to the Cullin1
E3 ligase complex for ubiquitination. The interaction between CAR and PGC1α also induces the
degradation of PGC1α and suppression of gluconeogenesis both in vitro and in vivo [220]. CAR can
induce carcinogenesis in mice, although this effect has not observed in humans [221]. Indeed,
CAR activation in humans may have antiproliferative effects, as demonstrated by a recent report
showing that CAR-deficient HepaRG cells have increased expression of proliferative genes [222].
FXR, highly expressed in liver, kidney, intestine, and adrenals, inhibits the expression of
CYP7A1 and sterol 12-α-hydroxylase (CYP8B1), genes involved in bile acid synthesis from cholesterol.
Besides its central role in bile acid metabolism, FXR activation also regulates the expression of
various genes involved in glucose, lipid, and lipoprotein metabolism, crucial in NAFLD [223].
Hepatic FXR inhibits fatty acid synthesis and uptake and upregulates beta oxidation, regulating
lipid homeostasis [224]. In NAFLD patients and in animal models, activation of FXR by obeticholic
acid (OCA) decreases both steatosis and obesity [225,226]. In HF/HC diet-treated mice, the FXR
agonist GW4064 decreased the expression of the hepatic lipid transporter CD36, reducing hepatic
steatosis and weight gain [227]. FXR can regulate insulin resistance as recently demonstrated in
NASH patients treated with OCA, which improves insulin sensitivity [228]. Similarly, OCA treatment
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in Zucker (fa/fa) rats improves insulin sensitivity, and GW4064 treatment, in HF/HC diet mice,
reduces hyperinsulinemia and hyperglycemia [226]. Besides OCA and GW4064, further potential
novel therapeutic targets in NASH are currently in phase II clinical development [229].
Intestinal activation of FXR reduces weight gain, liver glucose production and steatosis,
stimulating human fibroblast growth factor-19 (FGF19). This factor inhibits CYP7A1 resulting
in an inhibition of liver bile acid synthesis. Indeed, administration of FGF19 in mice and rats
animal models increases fat oxidation and decreases liver triglycerides and glucose levels [230,231].
Recent studies show that activation of intestinal FXR by feraxamine inhibits weight gain induced by
diet, hepatic glucose production and steatosis. These effects are mediated by fibroblast growth factor-15
signaling, without interfering with hepatic FXR activation [232]. Intestinal FXR agonism promotes
adipose tissue browning and reduces obesity and insulin resistance, suggesting that tissue-specific
activation of FXR may be a novel approach to treat NAFLD. Activation of intestinal FXR affords
hepatoprotection by restoring hepatic homeostasis, regulating cellular proliferation and decreasing
hepatic fibrosis and inflammation [233].
12. Pattern Recognition Receptors and the Inflammasomes
Toll-like receptors are highly conserved receptors that recognize endogenous danger signals,
such as molecules released by damaged cells (damage-associated molecular patterns, DAMPs)
or exogenous danger signals, as gut-derived pathogen-associated molecules (pathogen-associated
molecular patterns, PAMPs) [234,235]. Due to the high liver exposure to danger signals via the portal
system, TLR-induced pathways play a central role in activation of hepatic cells, primarily Kupffer
cells, but also hepatocytes and HSC. As pattern recognition receptors (PRR), TLRs act as defense
mechanism, but are also implicated in the pathogenesis of NASH [236,237]. Among NAFLD-related
TLRs, TLR2 interacts with a broad range of PAMPs, including peptidoglycan, a surface component of
Gram-positive bacteria [238], which appears to be increased in NAFLD [239]. Importantly, inhibition of
TLR2 signaling prevents insulin resistance in HFD mice [240], whereas TLR2-deficient mice fed HFD
display reduced levels of inflammatory cytokines and do not develop NASH [241].
The role of TLR5 in NAFLD pathogenesis is still unclear, as only a correlation with dysbiosis
and metabolic syndrome has been reported [242,243]. TLR9, an intracellular receptor, is activated
by unmethylated DNA, typically express in viruses and bacteria but rare in mammalian cells.
TLR9 downstream signaling involves IL-1, and is associated with NASH severity and fibrosis [244].
A study conducted in an experimental model of colitis, with high portal levels of LPS, shows increased
TLR9 liver expression, associated with hepatic steatosis, inflammation, and fibrosis [245].
The crucial role of TLR4 in NAFLD pathogenesis has been demonstrated in TLR4-deficient
mice, that display lower levels of inflammatory mediators and fail to develop NAFLD or insulin
resistance [246]. TLR4 plays a major role in linking innate immunity with inflammatory response
and the function of TLR4 in Kupffer cells is well characterized [247]. TLR4 is primarily activated by
Gram-negative bacterial lipopolysaccharides (LPS), leading to overexpression of cytokines, chemokines
and antimicrobial molecules [248,249]. LPS/TLR4 interaction, that requires LPS-binding protein
and two co-receptors (CD14 and myeloid differentiation protein 2, MD2), activates downstream
pathways in a myeloid differentiation factor (MyD)88-dependent or independent fashion [250].
The MyD88-dependent pathway signals through IκB kinase (IKK)/NF-κB and mitogen activated
protein kinase (MAPK)/AP-1, inducing the expression of pro-inflammatory cytokines (TNF-α, IL-1β,
IL-6 and IL-12) and genes implicated in the immune response [250]. The MyD88-independent cascade
involves IFNs [250]. ROS production and subsequent activation of the unfolded protein response are
also induced in TLR4-activated Kupffer cells, representing an additional mechanism triggered by TLRs
in NAFLD progression [251].
Besides Kupffer cells, TLR4 is expressed by other hepatic cells, including HSCs, hepatocytes
and cholangiocytes and LPS/TLR4 axis plays a critical role in the pathogenesis and progression
of fatty liver diseases, as demonstrated by increased levels of portal endotoxins and TLR4 hepatic
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expression in experimental NASH [252,253]. Based on its expression in HSC, a direct role of TLR4 in
liver fibrogenesis has been suggested. According to this hypothesis, the expression of chemokines and
adhesion molecules, as well as TGF-β-mediated signaling, are positively modulated by TLR4 [254],
while two TLR4 polymorphisms, protective against fibrosis, are associated with a lower apoptotic
threshold for HSC [255].
TLR4-mediated inflammatory response can also be elicited by DAMPs released by necrotic cells,
such as high mobility group box 1 (HMGB1) or phospholipids. These molecules stimulate monocyte
and Kupffer cells to secrete inflammatory mediators (Figure 3). It is noteworthy that, in the presence of
high glucose, TLR4 activation and downstream signaling can be triggered by FFA [256], clarifying,
at least in part, the mechanism by which saturated fatty acids, frequently enhanced in plasma of obese
patients, have toxic effects [257].Int. J. Mol. Sci. 2016, 17, 1575 14 of 33 
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Figure 3. Inflammasomes and the liver. In steatosis, hepatic damage leads to generation of damage-
associated molecular pattern (DAMPs), while alterations in microbiota lead to increased availability
of pathogen-associated molecular patterns (PAMPs). DAMPs and PAMPs act on receptors localized
on liver cells leading to activation of different inflammasomes and release of cytokines implicated in
NASH. NLRP3: NOD-like receptor family, pyrin domain containing 3; AIM2: Abscent in melanoma 2.
An important role in NASH pathogenesis has been recently ascribed to the nucleotide
oligomerization domain (NOD)-like receptors (NLRs). NLR activation in response to DAMPs or
PAMPs leads to the assembly of inflammasome, a multiprotein complex required for caspase-1
activity and initiation of inflammatory signals. Full activation of inflammasome, mediated by PRRs
via NF-κB, can be induced by a broad spectrum of signals, such as uric acid, ROS, ATP [258] and
mitochondrial DNA [259], and results in secretion of mature IL-1 and IL-18 [260,261]. These cytokines,
acting on different cell types, elicit inflammatory signals in liver as well as in the adipose tissue
and intestine, triggering steatosis, insulin resistance, inflammation and cell death [262]. A role
for inflammasomes in NAFLD development and progression to NASH has been shown both in
humans and animal models [263,264]. Activation of NLRP3 inflammasome has been reported in
MCD diet-induced steatohepatitis [265], as well following protracted HF/HC/HS feeding [266].
Moreover, NLRP3 gain of function correlates with liver fibrosis. Conversely, absence of this receptor
appears to improve metabolic activity [267] and diet-induced steatohepatitis [268], although a study
by Henao-Mejia et al. [269] demonstrated that lack of NLP3 promotes gut dysbiosis and chronic
inflammation. Activation of NLRP3 inflammasome has been associated with hepatocyte pyroptosis,
a recently described, inflammasome-mediated cell death mechanism [268,270].
Hepatocyte damage leads to secretion of intracellular molecules, DAMPs, acting as danger signals
capable to recruit and/or activate immune cells and initiate an inflammatory response in the absence
of pathogens, a mechanism referred as sterile inflammation [271,272]. Several DAMPs have been
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identified, including nuclear and mitochondrial DNA, purine nucleotides (ATP, UTP), nuclear factors
as HMGB1 and uric acid [180,273]. Besides mitochondrial DNA, which activates TLR9, a number
of mitochondrial components have been shown to play a part in sterile inflammation [274,275],
including formyl-peptides, ATP and ROS, that act by inducing inflammasome activation [276–278].
High concentrations of extracellular ATP, as a consequence of cell death, result in inflammasome
activation and IL-1β production, via P2X7 receptor [279]. As binding of ATP to P2X7 provokes pore
formation in the plasma membrane, allowing bacterial products to enter the cells, ATP plays a role
also in pathogen-associated molecular pattern-induced inflammation [280].
HMGB1 is a constitutively expressed nuclear protein that induces transcriptional activation [281],
and is released in response to different stimuli, such as PAMPs and DAMPs [282,283]. HMGB1 interacts
with a broad spectrum of receptors (TLR4, TLR2, TLR9, and RAGE) exerting proinflammatory actions
in complex with other factors, as single stranded DNA, LPS and IL-1β [284].
In its crystal form, uric acid induce inflammatory response by inflammasome activation in
a receptor-independent manner, causing phagosome burst and spill of cytosolic proteases [285].
In some settings, DAMPs can be also secreted independently of apoptosis. HMGB1 production can
occur by activated macrophages in response to LPS, TNF, and TGFβ [286]. Moreover, secondary necrosis,
due to impaired efferocytosis, may contribute to release of intracellular components amplifying the
inflammatory response.
13. Adipokines
Adipose tissue is recognized as an endocrine organ that secretes adipokines, which are peptides
with autocrine, paracrine and endocrine functions, controlling systemic metabolism and energy
homeostasis [287]. Among these, leptin and adiponectin are involved in the pathogenesis of
NAFLD and progression to NASH, leptin being identified as a profibrogenic adipokine [285,288].
Adipose tissue also produces other molecules (including classical cytokines), mostly released by
endothelial or immune cells, such as TNF-α and IL-6 [289]. Adiponectin has in general a beneficial
impact on NAFLD [290], while others, as resistin, TNF-α and IL-6 possibly have an adverse impact.
In particular, adiponectin reduces IR and shows anti-steatotic and anti-inflammatory properties,
while TNF-α increases IR and displays pro-inflammatory effects [291,292]. In physiologic conditions,
cytokine-adipokine interplay is finely regulated, but in some setting, such as increased adipose tissue
mass, the critical balance between cytokines and adipokines is compromised, leading to chronic
inflammation, IR and NAFLD [292]. Leptin, an adipokine which plays a major role in energy
homeostasis, is mainly produced by adipose tissue, but it is also synthesized in other organs [293].
Consequent to an increase in adipose tissue mass, leptin is upregulated, acting as compensatory
factor in preserving insulin sensitivity and exerting anti-steatotic effects. Nevertheless, if adipose
tissue continues to augment, the compensatory mechanism fails, with a sustained rise in IR and
hepatic steatosis [294]. Leptin-mediated dual action has been demonstrated in experimental NAFLD,
as in early disease leptin exerts a protective effect by inhibiting hepatic glucose production and
de novo lipogenesis through stimulation of fatty acid oxidation, while as NAFLD proceeds, it acts
as a pro-fibrogenic and inflammatory factor [294]. Novel evidence indicates that leptin-mediated
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase increases the levels of miR21, which is
a key regulator of TGF-β signaling. The rise in miR21 increases TGF-β and SMAD2/3-SMAD4 nuclear
colocalizations, whilst repressing SMAD7 [295]. In addition, leptin reduces PPAR-γ expression in
HSCs, promoting hepatic fibrosis [296]. A recent study, conducted by Heinrich et al., shows that leptin
resistance contributes to obesity in null mice mutated for carcinoembryonic antigen cell adhesion
molecule 1 (CEACAM1) [297]. CEACAM1 is a molecule that induces insulin clearance [298] and
reduces fatty acid synthesis in liver in the presence of insulin resistance, hepatic steatosis and visceral
obesity [299]. Furthermore, (Cc1−/−) mice develop hyperleptinemia, firstly related to the augmented
visceral obesity, followed by hyperphagia and reduced physical activity. These effects are possibly
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due to leptin resistance and elevated hypothalamic fatty acid synthase activity, that could, in turn,
be mediated by both central and peripheral factors [297].
Adiponectin is one of the most abundant adipokines, and is also produced by hepatocytes in
response to liver injury [300]. It exhibits anti-steatotic and antiapoptotic actions on hepatocytes and
exerts anti-inflammatory and anti-fibrotic effects acting on HSC, Kupffer and sinusoidal cells [301].
Adiponectin amounts drop when adipose mass increases, but the underlying mechanism is not
completely elucidated. It may involve adipose tissue hypoxia, oxidative stress [155,302] and increased
inflammatory mediator levels [303]. Another potential factor linking adipocyte hypertrophy to reduced
adiponectin synthesis is mitochondrial dysfunction [304]. Recent reports show that 11β-hydroxysteroid
dehydrogenase type1 (11β-HSD1) expression increases in hypertrophic adipocytes and this could be
responsible for mitochondrial dysfunction and reduced adiponectin synthesis.
After NASH progression towards cirrhosis, circulating adiponectin seems to increase [305],
probably due to two main mechanisms: a decrease in hepatic clearance of adiponectin and/or
a compensatory mechanism aimed to buffer the hyper-secretion of inflammatory cytokines.
Recent studies show that in the compensated late stage of NASH, circulating adiponectin is associated
with hepatic lipid loss [306]. These data reinforce the theory that adiponectin may be involved in the
“burnt-out NASH”, characterized by the loss of hepatic lipids, often observed in advanced fibrosis
and cirrhosis.
Adipose tissue (mainly visceral) and liver (mainly hepatocytes) are the principal producers of
chemerin [307]. Chemerin concentrations, which are generally higher in obesity and IR and drop
after weight loss, may modulate insulin resistance and inflammatory responses [308]. Animal models
of obesity and IR (ob/ob and db/db mice) display increased chemerin expression [309,310]. A recent
study conducted in NAFLD subjects show that circulating levels of chemerin positively correlate with
body mass index (BMI) and are also higher in individuals with impaired glucose tolerance (IGT) or
type 2 diabetes. In MCD-induced NASH, hepatic levels of chemerin tend to increase. In human NASH,
liver chemerin mRNA is upregulated in respect to healthy controls, but similar levels have been found
also in steatosis [311].
14. Microbiota
Accumulating evidence indicates that dysregulation of microbiota components are involved
in various liver diseases, including NAFLD and NASH, through obesity predisposition,
metabolic alterations and liver inflammation. Gut microbiota produces extra energy for the host,
processing polysaccharides to short-chain fatty acids (mainly acetate, propionate, and butyrate) [312]
and stimulating lipogenesis. A potential role of specific gut microbiome has been suggested in
the pathogenesis of NAFLD, as obese mouse models host 50% less Bacteroides and more Firmicutes
compared to lean control [313], and germ-free mice show significantly greater increase in body
fat following colonization with an “obese microbiome” [313]. Conversely, a recently described
bacterium, Akkermansia muciniphila, has been associated with a non-obese phenotype both in
humans and animal models, and HFD mice administered with Akkermansia show reduced adipose
tissue inflammation and increased glucose tolerance [314,315]. The intestinal microflora produces
enzymes that metabolize dietary choline, a cell membrane component regulating lipid transport
in liver, into methylamines, toxic compounds responsible for inflammation and liver injury [316].
Aberrant microbiota could induce triglyceride accumulation and promote NASH both reducing
choline and increasing methylamines [317].
Alterations in bile acid metabolism have been reported during NAFLD development.
Intestinal bacteria can modify bile acid pool through the conversion of cholic and chenodeoxycholic
acid into secondary bile acids, influencing lipid and glucose homeostasis. In addition, abnormal
microbiota can impair bile acid receptor signaling, such as FXR and the G-protein-coupled bile
acid-activated receptor TGR5 [318,319], affecting hepatic de novo lipogenesis and very low-density
lipoprotein VLDL export [320] as well as glucose metabolism [321,322].
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Endogenous ethanol is produced by several microbiome species. Ethanol induces hepatotoxicity
stimulating Kupffer cells to produce nitric acid and cytokines, whereas ethanol metabolites promote
triglyceride accumulation and oxidative stress in the liver. In addition, ethanol impairs gut mucosal
permeability inducing endotoxemia. Enhanced breath ethanol content was found in ob/ob mice and
it was abolished by antibiotic treatment [323]. Increased ethanol levels were also detected in obese
individuals and in children with NASH [324].
The gut microflora plays an important role in the development and function of the host immune
system [325]. Through the portal circulation, liver is directly exposed to gut-derived products, being the
first line of defense against bacterial toxins. Enhanced levels of circulating LPS and endotoxins have
been detected in rodents with diet-induced NAFLD and in NASH patients, respectively. LPS, the active
component of endotoxins, interacts with LPS-binding protein and the CD14 receptor, activating TLRs
and, consequently, the inflammatory cascade that involves stress-activated protein kinases, JNK,
p38, interferon regulatory factor-3 (IRF-3) and NF-κB, pathways implicated in insulin resistance and
triglycerides synthesis [252,325].
Finally, a correlation between small intestinal bacterial overgrowth (SIBO) and NAFLD has been
observed in clinical and experimental studies [237,326,327]. Bacterial overgrowth in the small intestine,
as well as qualitative microbiome abnormalities can impair the barrier functions of the intestinal
mucosa, leading to enhanced mucosa permeability and subsequent translocation of endotoxin to the
bloodstream [328,329]. Therefore, increased gut permeability represents an additional mechanism in
NASH pathogenesis, acting through the accumulation of endotoxin and bacterial metabolites in liver
and subsequent induction of inflammatory responses, via activation of pattern recognition receptors.
15. Perspectives
Extensive information has accumulated in the past few years on the molecular mechanisms
underlying the development of steatohepatitis. This has been paralleled by a number of clinical
trials exploring novel approaches, in part derived from preclinical data. Continuing research in this
field will be instrumental in providing new targets and biomarkers for the management of this very
prevalent condition.
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